{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:12:00Z","timestamp":1791317520098,"version":"4.3.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,15]]},"DOI":"10.1097\/qad.0b013e32835faa95","type":"journal-article","created":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T12:04:53Z","timestamp":1360670693000},"page":"1321-1329","source":"Crossref","is-referenced-by-count":16,"title":["Higher rates of AIDS during the first year of antiretroviral therapy among migrants"],"prefix":"10.1097","volume":"27","member":"276","reference":[{"key":"R1-15-20210130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","article-title":"Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.","volume":"367","author":"Braitstein","year":"2006","journal-title":"Lancet"},{"key":"R2-15-20210130","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00126334-200408010-00008","article-title":"Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.","volume":"36","author":"Nellen","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R3-15-20210130","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3851\/IMP1638","article-title":"Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands.","volume":"15","author":"Kesselring","year":"2010","journal-title":"Antivir Ther"},{"key":"R4-15-20210130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.healthpol.2008.09.016","article-title":"The five-year impact of an evolving global epidemic, changing migration patterns, and policy changes in a regional Canadian HIV population.","volume":"90","author":"Krentz","year":"2009","journal-title":"Health Policy"},{"key":"R5-15-20210130","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1097\/QAD.0b013e32832d4096","article-title":"Swiss HIV Cohort Study. African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study.","volume":"23","author":"Muler","year":"2009","journal-title":"AIDS"},{"key":"R6-15-20210130","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1097\/00002030-200310170-00012","article-title":"Swiss HIV Cohort Study. Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival.","volume":"17","author":"Staehelin","year":"2003","journal-title":"AIDS"},{"key":"R7-15-20210130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/cid\/cir814","article-title":"CASCADE Collaboration in EuroCoord. Uptake of combination antiretroviral therapy (cART) and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia.","volume":"54","author":"Jarrin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R9-15-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ije\/29.1.191","article-title":"The healthy migrant effect: not merely a fallacy of inaccurate denominator figures.","volume":"29","author":"Razum","year":"2000","journal-title":"Int J Epidemiol"},{"key":"R11-15-20210130","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multistate models.","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"R12-15-20210130","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1468-1293.2005.00304.x","article-title":"Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy.","volume":"6","author":"van den Berg","year":"2005","journal-title":"HIV Med"},{"key":"R13-15-20210130","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/157016210793499178","article-title":"Do HIV-infected immigrants initiating HAART have poorer treatment-related outcomes than autochthonous patients in Spain Results of the GESIDA 5808 Study.","volume":"8","author":"Perez Molina","year":"2010","journal-title":"Curr HIV Res"},{"key":"R14-15-20210130","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1097\/QAD.0b013e3283320dfd","article-title":"Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention.","volume":"23","author":"Grant","year":"2009","journal-title":"AIDS"},{"key":"R15-15-20210130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/QAD.0b013e3283366747","article-title":"FHDH-ANRS C04HIV-associated tuberculosis and immigration in a high-income country: incidence trends and risk factors in recent years.","volume":"24","author":"Abgrall","year":"2010","journal-title":"AIDS"},{"key":"R16-15-20210130","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1001\/jama.1992.03490120095035","article-title":"Tuberculosis and HIV infection in sub-Saharan Africa.","volume":"268","author":"De Cock","year":"1992","journal-title":"JAMA"},{"key":"R17-15-20210130","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/archinte.163.9.1009","article-title":"The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.","volume":"163","author":"Corbett","year":"2003","journal-title":"Arch Internal Med"},{"key":"R18-15-20210130","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/01.aids.0000194808.20035.c1","article-title":"Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.","volume":"19","author":"Lawn","year":"2005","journal-title":"AIDS"},{"key":"R19-15-20210130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/infdis\/jir421","article-title":"Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening.","volume":"204","author":"Sterling","year":"2011","journal-title":"J Infect Dis"},{"key":"R20-15-20210130","first-page":"1","article-title":"Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.","volume":"58","author":"Kaplan","year":"2009","journal-title":"Morb Mortal Wkly Rep"},{"key":"R23-15-20210130","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1128\/AAC.00341-07","article-title":"Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.","volume":"51","author":"Acosta","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-15-20210130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1468-1293.2007.00442.x","article-title":"Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.","volume":"8","author":"Mallolas","year":"2007","journal-title":"HIV Med"},{"key":"R25-15-20210130","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e318189a7df","article-title":"Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.","volume":"50","author":"Haas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-15-20210130","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/QAD.0b013e328329148e","article-title":"Clinical experience with the combined use of lopinavirritonavir and rifampicin.","volume":"23","author":"Lhomme","year":"2009","journal-title":"AIDS"},{"key":"R27-15-20210130","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1086\/597468","article-title":"Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.","volume":"48","author":"Mocroft","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R28-15-20210130","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/499952","article-title":"Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype.","volume":"42","author":"Vasan","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R29-15-20210130","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1086\/527416","article-title":"Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai Uganda, with incident HIV-1 infection.","volume":"197","author":"Kiwanuka","year":"2008","journal-title":"J Infect Dis"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e32835faa95","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:35:06Z","timestamp":1620970506000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201305150-00015"}},"subtitle":["the importance of tuberculosis"],"short-title":[],"issued":{"date-parts":[[2013,5,15]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32835faa95","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5,15]]}}}